Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Atypical Hemolytic Uremic Syndrome market Forecast. DelveInsight's Atypical Hemolytic Uremic Syndrome Market report offers an in-depth understanding of the ...

In May 2024, Novartis showcased the results from the 6-month double-blind phase of the Phase III APPEAR-C3G study for FABHALTA (iptacopan) at the late-breaking clinical trials session during the ...

基于ABR的疗效在治疗后第2年至第4年也保持稳定。Beqvez通常耐受性良好，安全性与 1/2期结果一致[6]。 Fabhalta（iptacopan）是由诺华研发的一款首创的口服、强效、选择性、可逆性补体因子B（FB）小分子抑制剂。它在免疫系统的替代补体途径中起作用，全面控制血管 ...

Novartis AG’s plan to sell its 70.6% stake in Novartis India is on track, CEO Vas Narasimhan confirmed at the World Economic Forum in Davos. Speaking to CNBC-TV18, he emphasised the company’s ...